Languages  By theme  By sector  By country
Page : 1 - 2 - ... 5 - 6 - 7 - 8 - 9 - 10 - 11 - ...
SANOFI-AVENTIS [FR0000120578/SAN]   
[03/06/2013]

SANOFI-AVENTIS : Sanofi Provides Update on Phase 3 Studies of Two Investigational Compounds

PRESS RELEASE Sanofi Provides Update on Phase 3 Studies of Two Investigational Compounds Paris, France - June 3, 2013 - Sanofi (EURONEXT: SAN and NYSE: SNY) today announced topline results of two Phase 3 clinical studies of its investigational compounds iniparib and otamixaban respectively. Iniparib The randomized Phase 3 ECLIPSE trial of iniparib in squamous non-small cell lung... See more
 
SANOFI-AVENTIS [FR0000120578/SAN]   
[23/05/2013]

SANOFI-AVENTIS : Sanofi appoints David Loew, Senior Vice President, Commercial Operations, Europe

PRESS RELEASE Sanofi appoints David Loew, Senior Vice President, Commercial Operations, Europe Paris, France - May 23, 2013 - Sanofi (EURONEXT : SAN and NYSE : SNY) is pleased to announce today the appointment of David Loew, as Senior Vice President, Commercial Operations, Europe, effective July 1st , 2013. He will report to Peter Guenter in his... See more
 
SANOFI-AVENTIS [FR0000120578/SAN]   
[23/05/2013]

SANOFI-AVENTIS : Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l'Autorité des Marchés Financiers (Regulation of the French stock market authority) Sanofi a French société anonyme... See more
 
SANOFI-AVENTIS [FR0000120578/SAN]   
[21/05/2013]

SANOFI-AVENTIS : Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine

PRESS RELEASE Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine -- Phase 2a study of the IL-4R alpha inhibitor, dupilumab, demonstrated 87% reduction in risk of asthma exacerbations in moderate-to-severe asthma patients with elevated eosinophils - Paris, France,... See more
 
SANOFI-AVENTIS [FR0000120578/SAN]   
[17/05/2013]

SANOFI-AVENTIS : Sanofi announces the next steps of its Research site in Toulouse, France

PRESS RELEASE Sanofi announces the next steps of its Research site in Toulouse, France Paris, France - May 17, 2013 - Today, the French ministerial mission presented the conclusions of its report regarding the Sanofi Research site in Toulouse, France. The report confirms the necessity to reorganize Sanofi's Research in France, in particular to address its structural weaknesses and... See more
 
SANOFI-AVENTIS [FR0000120578/SAN]   
[17/05/2013]

SANOFI-AVENTIS : Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis

PRESS RELEASE Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis Paris, France - May 17, 2013- Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that the pivotal study, JAKARTA, examining the selective JAK2 inhibitor SAR302503 for myelofibrosis (MF), met its primary endpoint in both dose... See more
 
SANOFI-AVENTIS [FR0000120578/SAN]   
[15/05/2013]

SANOFI-AVENTIS : Sanofi and Regeneron Announce Patient Enrollment in Two Phase 3 Trials with Sarilumab in Rheumatoid Arthritis (RA)

PRESS RELEASE Sanofi and Regeneron Announce Patient Enrollment in Two Phase 3 Trials with Sarilumab in Rheumatoid Arthritis (RA) - Comprehensive SARIL-RA development program to include 2,600 patients in four Phase 3 and one open-label extension trials - Paris, France and Tarrytown, NY - May 15, 2013 - Sanofi (EURONEXT: SAN and NYSE: SNY) and... See more
 
Page : 1 - 2 - ... 5 - 6 - 7 - 8 - 9 - 10 - 11 - ...
Videos
Gestionnaires,
Emetteurs,
My favourite companies
Most read news of SANOFI-AVENTIS
Dissemination technology Webdisclosure.com - copyright 2020 SYMEX ECONOMICS all rights reserved